Study says DPP-IV benefits may go beyond diabetes

Share this article:

DPP-IV diabetes medications may have benefits beyond insulin control. PharmaTimes reports that a Brigham and Women's Hospital study shows the medications may be associated with a reduced risk of autoimmune diseases among type-2 diabetics. PT says researcher Seoyoung Kim told reporters at the American College of Rheumatology conference that diabetics taking DPP-IV combination therapy were 34% less likely to develop RA and reduced their risk of other autoimmune diseases by 27%.

PT notes that the study is not definitive, but further evidence would benefit Merck's Januvia (which has seen sales slide) and the Boehringer Ingelheim/Eli Lilly drug Tradjenta. The DPP-IV class also includes the Bristol-Myers Squibb/AstraZeneca drug Onglyza.

The diabetes category as a whole is getting tighter. Merck noted in its conference call, for example, that "the DPP-IV market and branded worldwide diabetic market isn't growing." Additional pressures, such as being squeezed out of PBM formulary offerings have added to category pressures.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.